Home LiteratureArticle Details
PMID: 12960819 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.

AIDS (London, England) ·Vol. 17 ·No. 13 ·2003-09-05 ·Pages 1871-9

Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP

Abstract

The characterization of primary HIV infection by the analysis of serial plasma samples from newly infected persons using multiple standard viral assays. A retrospective study involving two sets of archived samples from HIV-infected plasma donors. (A) 435 samples from 51 donors detected by anti-HIV enzyme immunoassays donated during 1984-1994; (B) 145 specimens from 44 donors detected by p24 antigen screening donated during 1996-1998. Two US plasma products companies. The timepoints of appearance of HIV-1 markers and viral load concentrations during primary HIV infection. The pattern of sequential emergence of viral markers in the 'A' panels was highly consistent, allowing the definition and estimation of the duration of six sequential stages. From the 'B' panels, the viral load at p24 antigen seroconversion was estimated by regression analysis at 10 000 copies/ml (95% CI 2000-93 000) and the HIV replication rate at 0.35 log copies/ml/day, corresponding to a doubling time in the preseroconversion phase of 20.5 h (95% CI 18.2-23.4 h). Consequently, an RNA test with 50 copies/ml sensitivity would detect HIV infection approximately 7 days before a p24 antigen test, and 12 days before a sensitive anti-HIV test. The sequential emergence of assay reactivity allows the classification of primary HIV-1 infection into distinct laboratory stages, which may facilitate the diagnosis of recent infection and stratification of patients enrolled in clinical trials. Quantitative analysis of preseroconversion replication rates of HIV is useful for projecting the yield and predictive value of assays targeting primary HIV infection.

MeSH Terms
Biomarkers/blood Blood Donors Disease Progression HIV Antibodies/blood HIV Core Protein p24/blood HIV Infections/diagnosis,virology HIV Seropositivity/blood,diagnosis,virology HIV-1/isolation & purification Humans Immunoenzyme Techniques RNA, Viral/blood Retrospective Studies Viral Load Viremia/diagnosis,virology
Chemicals
Biomarkers HIV Antibodies HIV Core Protein p24 RNA, Viral
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Fiebig Eberhard W
Department of Laboratory Medicine, University of California, San Francisco, CA, USA.
Wright David J
Rawal Bhupat D
Garrett Patricia E
Schumacher Richard T
Peddada Lorraine
Heldebrant Charles
Smith Richard
Conrad Andrew
Kleinman Steven H
Busch Michael P
Article Info
Journal
AIDS (London, England)
Abbr.
AIDS
ISSN
0269-9370
Published
2003-09-05
Pages
1871-9
Language
English
Region
England
NLM ID
8710219
Subset
IM
Grants
NHLBI NIH HHS · N01-HB-47114 · United States
NIAID NIH HHS · U01-AI-41531 · United States
ODCDC CDC HHS · U64-CCU-902948 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com